The purpose of the study is to determine the ability of the drug panobinstat to control the growth of each of the tumour types and to describe the drug’s side effects. The drug is taken orally every day for up to 12 months. The effectiveness of the drug is measured through regular follow ups, including medical imaging.
Disease Stage: Relapsed/refractory and limited newly diagnosed
Patient Age Range: <40 years of age
Sample Size: 60
Recruitment period: 2 years
- National: ANZCHOG in partnership with ANZSA